Spotlight On... First FDA-approved 3-D manufactured drug hits the market; India's Biological E expanding capacity; SP Industries buys PennTech Machinery; and more...

The first FDA-approved drug produced using a 3-D printing is now on the market. Aprecia Pharmaceuticals said this week that it has launched its epilepsy drug, Spritam that is manufactured through three-dimensional printing technology. Spritam is a formulation of levetiracetam that uses the process so the pills rapidly disintegrate with a sip of liquid, making them easier to swallow. Aprecia has two facilities for manufacturing, one in Blue Ash, OH, where the company is headquartered, and one in East Windsor, NJ. A spokesperson said the company is currently investing $25 million in its 190,000-square-foot Blue Ash manufacturing facility. Here's the release

> India's Biological E says it is investing more than $75 million (Rs 500 crore) on new manufacturing facilities in the next three years to increase both vaccine and generics manufacturing. Report

> France's Novasep is partnering with GTP Technology to provide mAb production services for European clients. Release

> Warminster, PA-based SP Industries has bought the assets of Warminster, PA-based PennTech Machinery, which makes pharma manufacturing equipment. Release

Suggested Articles

AstraZeneca has signed a $750 million deal to produce up to 300 million doses of Oxford University's COVID-19 vaccine by year's end.

Racing with some COVID-19 vaccine heavyweights, Novavax has brought on a partner to manufacture adjuvant for its in-development shot. 

The FDA recently asked five drug manufacturers to recall the commonly used diabetes med metformin. With COVID-19 raging, is metformin just the start?